KR101769152B1 - 6-치환된 에스트라디올 유도체 및 사용 방법 - Google Patents

6-치환된 에스트라디올 유도체 및 사용 방법 Download PDF

Info

Publication number
KR101769152B1
KR101769152B1 KR1020107029911A KR20107029911A KR101769152B1 KR 101769152 B1 KR101769152 B1 KR 101769152B1 KR 1020107029911 A KR1020107029911 A KR 1020107029911A KR 20107029911 A KR20107029911 A KR 20107029911A KR 101769152 B1 KR101769152 B1 KR 101769152B1
Authority
KR
South Korea
Prior art keywords
cancer
group
alkyl
compound
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107029911A
Other languages
English (en)
Korean (ko)
Other versions
KR20110019767A (ko
Inventor
제임스 야거
Original Assignee
엔디씨, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔디씨, 엘엘씨 filed Critical 엔디씨, 엘엘씨
Publication of KR20110019767A publication Critical patent/KR20110019767A/ko
Application granted granted Critical
Publication of KR101769152B1 publication Critical patent/KR101769152B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
KR1020107029911A 2008-06-04 2009-06-03 6-치환된 에스트라디올 유도체 및 사용 방법 Expired - Fee Related KR101769152B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/132,857 US8168621B2 (en) 2005-09-30 2008-06-04 6-substituted estradiol derivatives and methods of use
US12/132,857 2008-06-04
PCT/US2009/046120 WO2009149176A1 (en) 2008-06-04 2009-06-03 6-substituted estradiol derivatives and methods of use

Publications (2)

Publication Number Publication Date
KR20110019767A KR20110019767A (ko) 2011-02-28
KR101769152B1 true KR101769152B1 (ko) 2017-08-17

Family

ID=41398499

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107029911A Expired - Fee Related KR101769152B1 (ko) 2008-06-04 2009-06-03 6-치환된 에스트라디올 유도체 및 사용 방법

Country Status (13)

Country Link
US (2) US8168621B2 (enExample)
EP (1) EP2300016B1 (enExample)
JP (1) JP5727370B2 (enExample)
KR (1) KR101769152B1 (enExample)
CN (1) CN102076343B (enExample)
AU (1) AU2009256237B2 (enExample)
BR (1) BRPI0913632A2 (enExample)
CA (1) CA2726364C (enExample)
DK (1) DK2300016T3 (enExample)
ES (1) ES2641779T3 (enExample)
MX (1) MX2010013288A (enExample)
NO (1) NO2300016T3 (enExample)
WO (1) WO2009149176A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1392313E (pt) * 2001-05-16 2007-07-17 Novartis Ag Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico
US10174070B2 (en) * 2005-09-30 2019-01-08 Endece Llc 6-substituted estradiol derivatives and methods of use
US20090028895A1 (en) * 2007-07-27 2009-01-29 Smith Walter P Methods and compositions for reducing facial lines and wrinkles
BR112013005843A2 (pt) * 2010-09-14 2019-12-10 Endece Llc derivativos de er-beta 6-substituído por desmetil-estradiol
MX354409B (es) * 2011-03-21 2018-03-05 Endece Llc Derivados de estradiol sustituidos en 6 para uso en remielinización de axones nerviosos.
US11624095B2 (en) 2017-09-27 2023-04-11 Case Western Reserve University Method of quantifying HIV reservoirs by induced transcription based sequencing
US20210024568A1 (en) * 2019-07-23 2021-01-28 Endece Llc Methods for modulation of lipoprotein lipase and apolipoprotein c2 expression and/or activity in the treatment of peripheral and central nervous system tissue disease states

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840943A (en) 1986-06-20 1989-06-20 Farmitalia Carlo Ebra S.R.L. Androst-4-ene-3,17-diones and process for their preparation
US6239123B1 (en) 1998-08-11 2001-05-29 Entremed, Inc. Use of estrogenic compounds as anti-fungal agents
US20080119447A1 (en) * 2005-09-30 2008-05-22 James Yarger 6-alkoxyalkyl estradiol derivatives and methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL122154C (enExample) 1963-10-18
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
GB8801697D0 (en) 1988-01-26 1988-02-24 Erba Farmitalia Improvements in synthesis of 6-methylene derivatives of androsta-1 4-diene-3 17-dione
US4904950A (en) 1988-11-04 1990-02-27 Medical Data Electronics, Inc. Telemetry digital subcarrier demodulator
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
JPH07215992A (ja) 1993-12-07 1995-08-15 Teikoku Hormone Mfg Co Ltd ６−又は７−置換アンドロスタ−１，４−ジエン誘導体
DE19633349A1 (de) 1996-08-19 1998-02-26 Sigma Tau Ind Farmaceuti Neue 6-Hydroxy- und 6-Oxo-androstan-Derivate, die auf das kardiovaskuläre System wirken und pharmazeutische Zusammensetzungen, die diese enthalten
US6784170B2 (en) * 2000-02-11 2004-08-31 Sri International Synthesis of anti-estrogenic and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one
IT1317031B1 (it) 2000-05-17 2003-05-26 Sigma Tau Ind Farmaceuti Procedimento migliorato per la preparazione di (e,z)3-(2-amminoetossimmino)-androstano-6, 17-dione e di suoi analoghi.
WO2002022645A2 (en) 2000-09-14 2002-03-21 Accelerated Pharmaceuticals, Inc. Method of making 7alpha-methyl-11beta-methoxy estradiol and related compounds with estrogenic activity
AU2004275693A1 (en) 2003-05-28 2005-04-07 Entremed, Inc. Antiangiogenic agents
US8088758B2 (en) * 2003-11-12 2012-01-03 Abbott Products Gmbh 17β-hydroxysteroid dehydrogenase type I inhibitors
WO2005070951A1 (en) 2004-01-16 2005-08-04 Cedarburg Pharmaceuticals, Inc. Exemestane and its intermediates and methods of making the same
US7419972B2 (en) * 2004-07-02 2008-09-02 Schering Ag 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
BRPI0616639A2 (pt) 2005-09-30 2011-06-28 Endece Llc compostos de exemestano de (s)-6-metiloxaalquila e métodos de uso relacionados
TWI392682B (zh) 2006-04-13 2013-04-11 Sigma Tau Ind Farmaceuti 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840943A (en) 1986-06-20 1989-06-20 Farmitalia Carlo Ebra S.R.L. Androst-4-ene-3,17-diones and process for their preparation
US6239123B1 (en) 1998-08-11 2001-05-29 Entremed, Inc. Use of estrogenic compounds as anti-fungal agents
US20080119447A1 (en) * 2005-09-30 2008-05-22 James Yarger 6-alkoxyalkyl estradiol derivatives and methods of use

Also Published As

Publication number Publication date
AU2009256237A1 (en) 2009-12-10
MX2010013288A (es) 2010-12-21
JP5727370B2 (ja) 2015-06-03
AU2009256237B2 (en) 2015-11-26
BRPI0913632A2 (pt) 2017-01-24
CA2726364C (en) 2016-10-11
WO2009149176A1 (en) 2009-12-10
US8629130B2 (en) 2014-01-14
DK2300016T3 (en) 2017-09-18
JP2011522825A (ja) 2011-08-04
CN102076343B (zh) 2015-04-01
EP2300016A1 (en) 2011-03-30
US20080312202A1 (en) 2008-12-18
US20120270817A1 (en) 2012-10-25
EP2300016B1 (en) 2017-08-09
CA2726364A1 (en) 2009-12-10
EP2300016A4 (en) 2012-01-18
ES2641779T3 (es) 2017-11-13
NO2300016T3 (enExample) 2018-01-06
US8168621B2 (en) 2012-05-01
CN102076343A (zh) 2011-05-25
KR20110019767A (ko) 2011-02-28

Similar Documents

Publication Publication Date Title
US10723757B2 (en) 6-substituted estradiol derivatives and methods of use
KR101769152B1 (ko) 6-치환된 에스트라디올 유도체 및 사용 방법
US20080119447A1 (en) 6-alkoxyalkyl estradiol derivatives and methods of use
CA2670773C (en) 6-alkoxyalkyl estradiol derivatives and methods of use
HK1139315B (en) 6-alkoxyalkyl estradiol derivatives and its use
HK1139315A (en) 6-alkoxyalkyl estradiol derivatives and its use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200811

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200811